Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer

Br J Surg. 2006 Jun;93(6):707-12. doi: 10.1002/bjs.5338.

Abstract

Background: This study analysed the value of [(18)F]fluorodeoxyglucose positron emission tomography (FDG-PET) in detecting axillary lymph node involvement in women with breast cancer.

Methods: In the first 150 women in this prospective study, axillary lymph node dissection (ALND) was performed regardless of the PET results. In a second group (125 women) FDG-PET was complemented with sentinel lymph node biopsy (SLNB) only in those who did not have pathological axillary uptake.

Results: The sensitivity and specificity of FDG-PET in detecting axillary involvement was 84.5 and 98.5 per cent respectively in the whole series of 275 patients, with two false-positive and 22 false-negative results. False-negative results were associated with some intrinsic tumour characteristics. In 21 women, PET revealed pathological uptake, suggesting involvement of the internal mammary lymph node chain. Whole-body PET identified a second synchronous tumour in five asymptomatic patients and haematogenous metastases in two patients.

Conclusion: The high positive predictive value of PET (98.4 per cent) suggests that FDG uptake in the axilla could be an indication for full ALND without previous SLNB.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Axilla / diagnostic imaging
  • Axilla / pathology
  • Breast Neoplasms / diagnostic imaging*
  • Breast Neoplasms / pathology
  • False Negative Reactions
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Lymph Node Excision / methods*
  • Lymph Nodes / diagnostic imaging*
  • Lymph Nodes / pathology
  • Lymphatic Metastasis / diagnostic imaging
  • Middle Aged
  • Positron-Emission Tomography / methods
  • Predictive Value of Tests
  • Prospective Studies
  • Radiopharmaceuticals*
  • Regression Analysis
  • Sensitivity and Specificity
  • Sentinel Lymph Node Biopsy / methods

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18